TrialHepatology (Baltimore, Md.)2017

Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.

Stefan Wirth et al.PubMed ↗Publisher ↗

No numbers read from the abstract.